These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38175450)

  • 1. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation.
    Farber RH; Stull DE; Witherspoon B; Evans CJ; Yonan C; Bron M; Dhanda R; Jen E; Brien CO'
    J Patient Rep Outcomes; 2024 Jan; 8(1):2. PubMed ID: 38175450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
    Jackson R; Brams MN; Carlozzi NE; Citrome L; Fritz NE; Hoberg AR; Isaacson SH; Kane JM; Kumar R
    J Clin Psychiatry; 2022 Nov; 84(1):. PubMed ID: 36449471
    [No Abstract]   [Full Text] [Related]  

  • 4. The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia.
    Trosch RM; Comella CL; Caroff SN; Ondo WG; Shillington AC; LaChappelle BJ; Hauser RA; Correll CU; Friedman JH
    J Clin Psychiatry; 2024 Jan; 85(1):. PubMed ID: 38270545
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.
    Tanner CM; Caroff SN; Cutler AJ; Lenderking WR; Shalhoub H; Pagé V; Franey EG; Serbin M; Yonan C
    J Patient Rep Outcomes; 2023 Mar; 7(1):21. PubMed ID: 36892733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.
    Caroff SN; Leong SH; Roberts CB; Berkowitz RM; Campbell EC
    J Clin Psychopharmacol; 2020; 40(4):373-380. PubMed ID: 32639290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
    Preskorn SH; Macaluso M
    J Psychiatr Pract; 2016 Mar; 22(2):117-23. PubMed ID: 27138080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study.
    Cutler AJ; Caroff SN; Tanner CM; Shalhoub H; Lenderking WR; Pagé V; Franey E; Yonan C
    J Am Psychiatr Nurses Assoc; 2023; 29(5):389-399. PubMed ID: 34154444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
    Dorfman BJ; Jimenez-Shahed J
    Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
    [No Abstract]   [Full Text] [Related]  

  • 12. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations.
    Jackson R; Brams MN; Citrome L; Hoberg AR; Isaacson SH; Kane JM; Kumar R
    Neuropsychiatr Dis Treat; 2021; 17():1589-1597. PubMed ID: 34079257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop.
    Kane JM; Correll CU; Nierenberg AA; Caroff SN; Sajatovic M;
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29742330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.
    Huang Y; Pan L; Teng F; Wang G; Li C; Jin L
    Shanghai Arch Psychiatry; 2017 Oct; 29(5):295-303. PubMed ID: 29276353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.
    Caroff SN; Yeomans K; Lenderking WR; Cutler AJ; Tanner CM; Shalhoub H; Pagé V; Chen J; Franey E; Yonan C
    J Clin Psychopharmacol; 2020; 40(3):259-268. PubMed ID: 32332461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.